ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas
<div>A collaboration was established between the European Society of Gynaecological Oncology (ESGO), the European Reference Network on Rare Adult Solid Cancers (EURACAN), and the Gynecologic Cancer InterGroup (GCIG) with the aim of developing clinically relevant, evidence-based consensus guidelines on the management of patients with uterine sarcomas from diagnosis to relapse.</div><div>ESGO/EURACAN/GCIG nominated practicing clinicians from centers of expertise in the management of patients with uterine sarcomas to serve on the expert panel (25 experts). To ensure that the statements were evidence-based, data identified from a systematic search were reviewed and critically appraised. In the absence of robust scientific evidence, clinical recommendations were based on the consensus of the international development group. Prior to publication, the guidelines were reviewed by 104 independent international clinicians with expertise in uterine sarcomas.</div><div>Attention was given to imaging, pathology, and molecular analyses in addition to clinical management. Recommendations for surgery, including specific recommendations at initial diagnosis and at relapse, were developed. Indications for radiation and systemic therapies, including chemotherapy options, endocrine therapies, and targeted therapies, were addressed for the following histological subgroups of uterine sarcomas: high-grade endometrial stromal sarcomas, undifferentiated sarcomas, low-grade endometrial stromal sarcomas, uterine leiomyosarcomas, adenosarcomas, and selected very rare entities. Recommendations for follow-up and highlighted issues and unmet needs faced by long-term survivors were also discussed.</div>
Authors
- Jalid Sehouli (ORCID: https://orcid.org/0000-0002-5963-6623)
- Sarah Chiang (ORCID: https://orcid.org/0000-0001-9698-0936)
- D. Fischerová (ORCID: https://orcid.org/0000-0002-7224-3218)
- Ignacio Zapardiel (ORCID: https://orcid.org/0000-0002-9175-7767)
- Michael Leonard Friedlander (ORCID: https://orcid.org/0000-0003-3090-795X)
- Javier Martín‐Broto (ORCID: https://orcid.org/0000-0001-7350-6916)
- Frédéric Amant (ORCID: https://orcid.org/0000-0002-5452-4905)
- Se Ik Kim (ORCID: https://orcid.org/0000-0002-9790-6735)
- Angelo Paolo Dei Tos (ORCID: https://orcid.org/0000-0002-1228-8940)
- Paolo G. Casali (ORCID: https://orcid.org/0000-0003-4056-8023)
- Sabrina Croce (ORCID: https://orcid.org/0000-0002-6487-5418)
- Martee L. Hensley (ORCID: https://orcid.org/0009-0004-9956-1306)
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Jae‐Weon Kim (ORCID: https://orcid.org/0000-0003-1835-9436)
- Rick L. M. Haas
- Robin L. Jones (ORCID: https://orcid.org/0000-0003-4173-3844)
- Antonio Casado (ORCID: https://orcid.org/0000-0002-8200-3306)
- Albiruni R. Abdul Razak (ORCID: https://orcid.org/0000-0001-7657-9950)
- Roberta Sanfilippo (ORCID: https://orcid.org/0000-0002-9704-0521)
- Mehmet Mutlu Meydanlı (ORCID: https://orcid.org/0000-0001-6763-9720)
- Patricia Pautier (ORCID: https://orcid.org/0000-0002-1459-268X)
- Winan J. van Houdt (ORCID: https://orcid.org/0000-0002-2303-3468)
- Isabelle Laure Ray-Coquard (ORCID: https://orcid.org/0000-0003-2472-8306)
- Fiona M. Fennessy (ORCID: https://orcid.org/0000-0001-9717-7715)
- François Planchamp (ORCID: https://orcid.org/0000-0002-8709-0410)
- Peter Hohenberger
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Brigham and Women's Hospital (US)
- New South Wales Department of Health (AU)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- University of Padua (IT)
- Seoul National University (KR)
- University of Toronto (CA)
- University of Milan (IT)
- Cornell University (US)
- Charles University (CZ)
- Heidelberg University (DE)
- Royal Hospital for Women (AU)
- Leiden University Medical Center (NL)
- Hospital Universitario La Paz (ES)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- The Netherlands Cancer Institute (NL)
- Hospital Clínico San Carlos (ES)
- Centre Léon Bérard (FR)
- Oncode Institute (NL)
- Medical Park Gaziantep Hospital (TR)
- Health Services and Performance Research Laboratory (FR)
- Royal Marsden Hospital (GB)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Institut Bergonié (FR)
- University Medical Centre Mannheim (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- General University Hospital in Prague (CZ)
- Charité - Universitätsmedizin Berlin (DE)
- KU Leuven (BE)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1136/ijgc-2024-005823
- Citations
- 33
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 19.23
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Karyopharm Therapeutics
- Intuitive Surgical
- Novocure
- Foghorn Therapeutics
- Arog Pharmaceuticals
- BeiGene
- Iterion Therapeutics
- Eisai
- PharmaMar
- Symphogen
- Genentech
- Chugai Pharmaceutical
- Bayer Vital
- Sanofi-Aventis Deutschland
- European Network for Rare Adult Solid Cancers
- Daiichi Sankyo Europe